Group 1 - Healthblooming Limited increased its stake in Brainstorm Cell Therapeutics Inc. (06681) by acquiring 1.2 million shares at a price of HKD 4.6927 per share, totaling approximately HKD 5.6312 million [1] - Following this transaction, Healthblooming Limited's total shareholding in Brainstorm Cell Therapeutics Inc. reached 82.104 million shares, representing a 6.04% ownership stake [1] - The transaction involved other related parties, specifically Zhao Yujie [1]

本次交易涉及关联方：麦叶青。 香港联交所最新数据显示，2月11日，TURING INNOVATION LIMITED增持中国科创产业投资 (00339)133万股，每股均价0.765港元，总金额约为101.75万港元。增持后最新持股数目约为1.08亿股， 最新持股比例为25.11%。 ...

香港联交所最新数据显示，2月9日，摩根大通增持微创医疗(00853)89.1713万股，每股作价11.089港 元，总金额约为988.82万港元。增持后最新持股数目约为1.92亿股，持股比例为10.02%。 ...

及何崇本博士及何世荣先生各自提供的个人担保作抵押，据此，X8Finance同意(其中包括)根据有关协 议的条款及按照其中所载条件向亨景提供2026年2月贷款;及与联旺(香港)有限公司(联旺)及何世荣先生 (作为共同借款人)订立补充贷款协议将本金金额为3500万港元的2025年7月贷款II延期，该贷款以联旺 (作为抵押人)提供的物业II的现有第二按揭作抵押，据此，X8Finance同意将2025年7月贷款II的还款日期 由2026年2月13日起延长12个月。 零在科技金融(00093)发布公告，于2026年2月13日，本公司的间接全资附属公司X8Finance(作为放款 人)：与亨景有限公司(亨景，作为借款人)订立2026年2月贷款协议以提供本金金额为1.03亿港元的2026 年2月贷款，该贷款以亨景(作为抵押人)提供的物业I的第一按揭;何崇本博士(作为抵押人)提供的物业III 的第一按揭。 ...

Core Viewpoint - Major tech companies are increasing their spending plans on artificial intelligence infrastructure, yet Nvidia's stock price has remained stagnant for months despite being a key beneficiary of this investment trend [1][4]. Group 1: Nvidia's Stock Performance - Nvidia's stock has seen less than a 1% increase since early Q4 of last year, despite reaching an all-time high in late October [1]. - The stock's performance in early 2026 is only slightly outperforming the S&P 500, showing a slowdown compared to nearly 40% growth in 2025 [1]. - Currently, Nvidia's stock price is approximately 24 times its expected earnings, which is in line with the Nasdaq 100 and slightly above the S&P 500, but still significantly lower than its five-year average of 38 times [4]. Group 2: Capital Expenditure and Market Sentiment - Companies like Meta, Alphabet, Microsoft, and Amazon are expected to increase their capital expenditures to over $600 billion by 2026, but concerns about the returns on these investments have not significantly boosted stock prices [1]. - Analysts express worries that the ultimate benefits of AI may not keep pace with the announced capital expenditures, potentially leading to market saturation and a pause in investments [4]. - Despite the anticipated growth in Nvidia's sales by 58% this year and 28% by 2027, the valuation of Nvidia is under pressure due to expected slowdowns in revenue growth [4]. Group 3: Analyst Perspectives - Analysts have not significantly changed their revenue and profit forecasts for Nvidia for 2026 since the announcement of spending plans by major tech firms, indicating a wait-and-see approach [5]. - Market sentiment can shift rapidly, and stocks like Nvidia may experience natural consolidation periods after significant price increases [6].

Core Viewpoint - The company announced that there were no unallocated shares from the rights issue available for placement, resulting in no net proceeds to be distributed to non-participating shareholders [1] Summary by Relevant Sections - **Rights Issue Results**: A total of 87.1231 million shares will be issued, which represents approximately 9.71% of the total shares available for subscription under the rights issue [1]

紫荆国际金融(08340)发布公告，，季毅女士(季女士)已辞任执行董事的职位，自2026年2月13日起生 效，因彼希望投入更多时间处理其他业务。 ...

OKURA HOLDINGS(01655)公布，已于2026年2月13日完成配售8498万股配售股份，每股配售股份0.143 港元，净筹约1038万港元，约50%及30%分别用作(a)购买日式弹珠机及日式角子机;及(b)翻新或提升本 集团现有日式弹珠机游戏馆以及市场推广开支，而余下约20%则用作集团其他一般营运资金 ...

中自科技(688737.SH)披露2026年限制性股票激励计划(草案)，拟授予的限制性股票数量为206.2238万 股，约占激励计划草案公告时公司股本总额的1.72%。本次授予为一次性授予，无预留权益。授予的激 励对象共计68人，授予价格为13.96元/股。 ...

由于已注销的购股权将被视为已动用，以计算该计划项下的计划授权上限及服务提供者分项限额，故计 划授权上限及服务提供者分项限额项下可供未来授出的股份数目分别维持约726.15万股及478.99万股。 中国卫生集团(00673)发布公告，于2026年2月13日，根据该计划的条款，董事会透过向承授人发出书面 通知宣布该等购股权据此注销，以行使酌情权悉数注销于2026年2月2日授出且任何承授人未有效行使的 4063.8万份购股权。 ...